Bidirectional functions of arsenic as a carcinogen and an anti-cancer agent in human squamous cell carcinoma

PLoS One. 2014 May 9;9(5):e96945. doi: 10.1371/journal.pone.0096945. eCollection 2014.

Abstract

Bidirectional cancer-promoting and anti-cancer effects of arsenic for cancer cells have been revealed in previous studies. However, each of these effects (cancer-promoting or anti-cancer) was found in different cells at different treated-concentration of arsenic. In this study, we for the first time indicated that arsenic at concentration of 3 µM, equal to average concentration in drinking water in cancer-prone areas in Bangladesh, simultaneously expressed its bidirectional effects on human squamous cell carcinoma HSC5 cells with distinct pathways. Treatment with 3 µM of arsenic promoted cell invasion via upregulation of expression of MT1-MMP and downregulation of expression of p14ARF and simultaneously induced cell apoptosis through inhibition of expression of N-cadherin and increase of expression of p21(WAF1/CIP1) at both transcript and protein levels in HSC5 cells. We also showed that inhibition of MT1-MMP expression by NSC405020 resulted in decrease of arsenic-mediated invasion of HSC5 cells involving decrease in phosphorylated extracellular signal-regulated kinases (pERK). Taken together, our biological and biochemical findings suggested that arsenic expressed bidirectional effects as a carcinogen and an anti-cancer agent in human squamous cell carcinoma HSC5 cells with distinct pathways. Our results might play an important scientific evident for further studies to find out a better way in treatment of arsenic-induced cancers, especially in squamous cell carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / toxicity*
  • Apoptosis / drug effects
  • Arsenic / pharmacology*
  • Arsenic / toxicity*
  • Cadherins / genetics
  • Cadherins / metabolism
  • Carcinogens / pharmacology*
  • Carcinogens / toxicity*
  • Carcinoma, Squamous Cell / pathology*
  • Cell Line, Tumor
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Dose-Response Relationship, Drug
  • Down-Regulation / drug effects
  • Humans
  • Matrix Metalloproteinase 14 / genetics
  • Matrix Metalloproteinase 14 / metabolism
  • Matrix Metalloproteinase Inhibitors / pharmacology
  • Neoplasm Invasiveness
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Tumor Suppressor Protein p14ARF / genetics
  • Tumor Suppressor Protein p14ARF / metabolism
  • Up-Regulation / drug effects

Substances

  • Antineoplastic Agents
  • Cadherins
  • Carcinogens
  • Cyclin-Dependent Kinase Inhibitor p21
  • Matrix Metalloproteinase Inhibitors
  • RNA, Messenger
  • Tumor Suppressor Protein p14ARF
  • Matrix Metalloproteinase 14
  • Arsenic

Grants and funding

This research is funded by Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 106-NN.02-2013.07. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.